Meanwhile, immunosuppressive cells such as tumor-associated macrophages (TAMs) and regulatory T cells (Tregs) in TME secrete cytokines that blunt ADCC-mediated tumor killing by NK cells, weakening the efficacy of trastuzumab in HER2+ breast cancer. The gene discussed is ERBB2; the disease is breast cancer.